Zacks Investment ResearchThu, 07 May 2026 16:16:31 GMTMonte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue EstimatesGLUE-0.78%
The Motley FoolTue, 21 Apr 2026 17:33:49 GMTMonte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital RaiseGLUE-0.78%
Zacks Investment ResearchTue, 17 Mar 2026 13:26:09 GMTMonte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue EstimatesGLUE-0.78%
Zacks Investment ResearchThu, 12 Mar 2026 15:01:21 GMTMonte Rosa Therapeutics (GLUE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?GLUE-0.78%